Form 4: Immunome Director James P. Boylan Granted Stock Options, Disclaims Personal Ownership for Enavate Sciences

Immunome Inc. Director James P. Boylan was granted 18,864 stock options with an exercise price of $9.57, though he disclaims beneficial ownership, holding them for the benefit of Enavate Sciences, LP.

Summary

• Immunome Inc. (IMNM) Director James P. Boylan was granted 18,864 Director Stock Options on June 10, 2025.
• The exercise price for these options is $9.57 per share.
• The options are for 18,864 shares of Common Stock.
• Mr. Boylan has disclaimed beneficial ownership of these securities, stating he will receive and hold them for the benefit of Enavate Sciences, LP.
• The options will vest in four quarterly installments, commencing from June 10, 2025, until the one-year anniversary thereafter, subject to Mr. Boylan's continuous service with the Company.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it indicates a standard compensation practice for a director, aligning interests, even if indirectly. There are no negative financial implications or red flags from this specific filing.

Positives

• The grant of stock options to a director aligns management incentives with shareholder interests, even if indirectly through Enavate Sciences, LP.
• The vesting schedule encourages continued service and commitment from the director.

Risks

• The vesting of the options is subject to Mr. Boylan's continuous service with Immunome Inc., meaning the options could be forfeited if his service ceases before full vesting.

Future Outlook

The stock options granted to Director James P. Boylan are set to vest in four quarterly installments over one year, commencing June 10, 2025, contingent on his continuous service, indicating an expectation of his ongoing involvement with the company.

Management Comments

• "Mr. Boylan has agreed to receive and hold for the benefit of Enavate Sciences, LP, any securities granted to him for his service as a director on the Company's board of directors."
• "As such, Mr. Boylan disclaims beneficial ownership of, and all right, title and interest in, the reported securities."

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically a stock option grant to a director. Such grants are common practice in the biotechnology and pharmaceutical industries, like Immunome, to attract and retain executive talent and align their interests with long-term company performance. The disclaimer of beneficial ownership by the director, in favor of an entity like Enavate Sciences, LP, suggests a specific corporate or investment structure related to the director's appointment or compensation arrangement.

Corporate Governance

Related Party Transactions

• James P. Boylan, a director of Immunome Inc., has agreed to receive and hold the granted securities for the benefit of Enavate Sciences, LP, and disclaims beneficial ownership. This indicates a relationship where the director's compensation is directed to a third-party entity.

Stakeholder Impact

• Shareholders: The grant of options is a form of non-cash compensation that aligns the director's interests with the company's stock performance, potentially benefiting shareholders if the stock price increases. The disclaimer of direct beneficial ownership by the director in favor of Enavate Sciences, LP, means the direct personal financial incentive for the director is channeled through this entity.
• Employees: No direct impact mentioned.

Next Steps

• The stock options will vest in four quarterly installments, commencing from June 10, 2025, over the subsequent year, subject to continuous service.

Key Dates

Keywords

Immunome Inc., IMNM, SEC Form 4, Stock Options, Insider Transaction, Director Compensation, Equity Grant, Enavate Sciences, Beneficial Ownership